Discover updated strategies for treating leukemia and lymphomas during pregnancy, emphasizing delayed delivery, chemotherapy safety, and multidisciplinary care for optimal maternal and fetal health.
In a recent interview with Contemporary OB/GYN, Giselle Kidson-Gerber, MD, a hematologist with expertise in obstetric hematology, shared insights into new guidelines for managing hematological malignancies during pregnancy, specifically acute leukemia and aggressive lymphomas.
These conditions pose significant risks to maternal and fetal health, but advancements in management provide hope for better outcomes. Acute leukemia is life-threatening if untreated, with symptoms such as anemia, infection, and bleeding, although it is often detected through routine blood work during pregnancy. Aggressive lymphomas, on the other hand, may present with masses in the neck, chest, or abdomen, often identified through obstetric ultrasounds, or symptoms such as shortness of breath, fevers, or night sweats.
The guidelines emphasize the importance of delaying birth to optimize fetal neurocognitive development. Evidence shows that gestational age at delivery has a greater impact on long-term outcomes than in utero exposure to chemotherapy. Women diagnosed in the second or early third trimester are encouraged to undergo chemotherapy during pregnancy rather than opting for early delivery. PET scans, critical for diagnosing and monitoring lymphomas, are now considered safe during pregnancy when proper modeling of fetal radiation exposure is conducted. The guidelines also address breastfeeding and include data on the limited use of newer treatment agents during pregnancy.
A multidisciplinary approach is essential for managing these complex cases. Collaboration among maternal-fetal medicine specialists, obstetricians, hematologists, midwives, nurses, and allied health professionals ensures comprehensive care. Effective communication, seamless coordination, and detailed documentation are critical, especially in settings where hospital services may be physically separated. The guidelines stress the importance of creating a written management plan covering all trimesters, delivery, and postpartum care to guide both patients and health care teams.
The key clinical takeaways focus on avoiding premature decisions such as early termination or delivery, involving a multidisciplinary team, and reassuring patients that positive outcomes are achievable. Kitson-Gerber highlighted that most women with hematological malignancies can be treated effectively during pregnancy and encouraged health care providers to consult the guidelines for evidence-based strategies. With expert support and collaborative care, health care teams can help ensure favorable outcomes for both mother and child in these high-risk scenarios.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Socioeconomic disadvantage in pregnancy linked to postpartum CVD risk
February 19th 2025A new study highlights how neighborhood-level socioeconomic deprivation in early pregnancy significantly raises the long-term risk of cardiovascular disease in postpartum women, emphasizing the role of social determinants in maternal health.
Read More
Regulatory T cell alterations in early pregnancy linked to spontaneous preterm labor
February 18th 2025A recent study reveals that specific Treg subpopulation changes in the first trimester may contribute to spontaneous preterm labor, shedding light on the role of immune regulation in pregnancy outcomes.
Read More